Source:http://linkedlifedata.com/resource/pubmed/id/19050678
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2009-1-6
|
pubmed:abstractText |
Post-translational degradation of protein plays an important role in cell life. We employed chimeric molecules (dihydrotestosterone-based proteolysis-targeting chimeric molecule [DHT-PROTAC]) to facilitate androgen receptor (AR) degradation via the ubiquitin-proteasome pathway (UPP) and to investigate the role of AR in cell proliferation and viability in androgen-sensitive prostate cancer cells. Western blot analysis and immunohistochemistry were applied to analyse AR levels in LNCaP cells after DHT-PROTAC treatment. Cell counting and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) cell viability assay were used to evaluate cell proliferation and viability after AR elimination in both LNCaP and PC-3 cells. AR was tagged for elimination via the UPP by DHT-PROTAC, and this could be blocked by proteasome inhibitors. Degradation of AR depended on DHT-PROTAC concentration, and either DHT or an ALAPYIP-(arg)(8) peptide could compete with DHT-PROTAC. Inhibition of cell proliferation and decreased viability were observed in LNCaP cells, but not in PC-3 or 786-O cells after DHT-PROTAC treatment. These data indicate that AR elimination is facilitated via the UPP by DHT-PROTAC, and that the growth of LNCaP cells is repressed after AR degradation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Dihydrotestosterone,
http://linkedlifedata.com/resource/pubmed/chemical/Proteasome Endopeptidase Complex,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Ubiquitin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1008-682X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
11
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
119-26
|
pubmed:meshHeading |
pubmed-meshheading:19050678-Cell Line, Tumor,
pubmed-meshheading:19050678-Cell Proliferation,
pubmed-meshheading:19050678-Cell Survival,
pubmed-meshheading:19050678-Dihydrotestosterone,
pubmed-meshheading:19050678-Dose-Response Relationship, Drug,
pubmed-meshheading:19050678-Humans,
pubmed-meshheading:19050678-Male,
pubmed-meshheading:19050678-Prostatic Neoplasms,
pubmed-meshheading:19050678-Proteasome Endopeptidase Complex,
pubmed-meshheading:19050678-Receptors, Androgen,
pubmed-meshheading:19050678-Recombinant Fusion Proteins,
pubmed-meshheading:19050678-Signal Transduction,
pubmed-meshheading:19050678-Ubiquitin
|
pubmed:year |
2009
|
pubmed:articleTitle |
Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells.
|
pubmed:affiliation |
Department of Urology, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, China
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|